Totaligent, Inc.

Item 1.01 Entry into a Material Definitive Agreement. On March 22, 2026, Totaligent, Inc. (the “Company”) entered into an Extension Amendment (the “Amendment”) to the Binding Letter of Intent dated February 22, 2026 (the “LOI”) with GloMed Solutions Limited Liability Company (“GloMed”). As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 23, 2026, the LOI sets forth the principal terms for a proposed transaction pursuant to which the Company and GloMed would form a joint venture and the Company would receive a call option to acquire GloMed, including its business operations, intellectual property, and related assets. The Amendment extends the target date for the negotiation and execution of definitive agreements (including, but not limited to, joint venture agreements, asset contribution agreements, intellectual property assignment agreements, and related transaction documents), and the target closing date of the transaction, to April 22, 2026, to allow additional time for completion of negotiations and due diligence. The binding exclusivity period set forth in the LOI has been extended through April 22, 2026, or such earlier date as provided in the LOI, and is not affected by the Amendment. Except as expressly amended, all terms and conditions of the LOI remain in full force and effect. The foregoing description is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.